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Abstract 
Background: The research program CARPEM (cancer research and personalized medicine) brings together the 
expertise of researchers and hospital‑based oncologists to develop translational research in the context of personal‑
ized or “precision” medicine for cancer. There is recognition that patient involvement can help to take into account 
their needs and priorities in the development of this emerging practice but there is currently no consensus about 
how this can be achieved. In this study, we developed an empirical ethical research action aiming to improve patient 
representatives’ involvement in the development of the translational research program together with health profes‑
sionals. The aim is to promote common understanding and sharing of knowledge between all parties and to establish 
a long‑term partnership integrating patient’s expectations.
Methods: Two distinct committees were settled in CARPEM: an “Expert Committee”, gathering healthcare and 
research professionals, and a “Patient Committee”, gathering patients and patient representatives. A multidisciplinary 
team trained in medical ethics research ensured communication between the two committees as well as analysis of 
discussions, minutes and outputs from all stakeholders.
Results: The results highlight the efficiency of the transfer of knowledge between interested parties. Patient repre‑
sentatives and professionals were able to identify new ethical challenges and co‑elaborate new procedures to gather 
information and consent forms for adapting to practices and recommendations developed during the process. 
Moreover, included patient representatives became full partners and participated in the transfer of knowledge to the 
public via conferences and publications.
Conclusions: Empirical ethical research based on a patient‑centered approach could help in establishing a fair 
model for coordination and support actions during cancer research, striking a balance between the regulatory frame‑
work, researcher needs and patient expectations. Our approach addresses the concept of translational ethics as a way 
to handle the main remaining gap between combining care and research activities in the medical pathway and the 
existing framework.
Keywords: Medical ethics, Personalized medicine, Patient‑centered approach, Translational research, Translational 
ethics
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Background
The underlying promise of personalized/precision medi-
cine is to adapt diagnosis, treatment and prevention 
to patients according to their genetic and molecular 
profile, lifestyle and environments. This concept has 
been strengthened by many therapeutic and diagnostic 
advancements in oncology [1–5]. The challenge is both 
to accelerate the translation of biomedical research to 
therapeutic application [6]—from bench to bedside and 
to use patient samples and data and samples for research 
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the laboratory research environment—from bedside to 
bench to bedside [7].
Yet, personalized medicine is not a continuum; indeed, 
it results from a complex and still-emerging approach to 
medicine that underlies ongoing translational research 
(TR) programs. TR relies in part on non-interventional 
research, and the emergence of next-generation sequenc-
ing technologies for personalized medicine blurs the 
traditional dichotomy between research and clinical 
practice. TR is driven by the outgrowth of infrastruc-
tures gathering health data and samples on a large scale. 
It relies on the combination of clinical, genomic, biologi-
cal data as well as the availability of biological material in 
resource centers. It also relies on the de-compartmental-
ization of data gathered at national, pan-national or dis-
ease levels [8, 9]. A growing body of literature highlights 
the need to rethink the current bioethical and regulatory 
frameworks [7, 10–14] and as Nicol et  al. [13] postu-
late, to reformulate in this context the classical tensions 
between community welfare and individual liberty, risk 
and benefit, and autonomy and paternalism. Indeed, on 
one hand, data and samples may be re-used in future 
unknown research and on the other, genetic or genomic 
analysis may result in a diagnostic or therapeutic applica-
tion and in proposals to participate in a clinical trial of 
precision medicine [15–17].
CARPEM (cancer research for personalized medicine) 
is a French consortium certified in 2013 which devel-
ops translational research in the context of personalized 
or “precision” medicine for cancer. CARPEM’s goals 
are to perform innovative and efficient translational 
research, stimulate data sharing and collaboration among 
researchers, and accelerate the translation of biomedical 
research to therapeutic application to benefit patients. 
To achieve these goals, CARPEM developed three inte-
grated research programs. Two are scientific TR ones, 
dealing with complementary approaches of personalized 
medicine (genomic and cellular). The third is an empir-
ical-ethical research program exploring the feasibility of 
building, together with patients and patient representa-
tives, some ethical guidelines to bridge the persistent 
although inappropriate division between research ethics 
and medical ethics.
In this paper, we describe the establishment, method-
ology and first results of the empirical-ethical research 
program of CARPEM. We describe how the mediation 
between two independent ethics committees by a mul-
tidisciplinary team of researchers specialized in medical 
ethics allowed for (1) the transfer of knowledge between 
parties ensuring a path to transparency for the public and 
(2) the identification and handling of ethical issues jointly 
by professionals and patient representatives. Finally, 
we discuss how we are thinking the translational ethics 
approach to establish a fair model for coordination and 
support actions in TR, striking a balance between the 
French legal framework, researcher needs and patient 
expectations. With such an empirical approach, we aim 
to surpass the limitations of abstract ethical reasoning 
and address “real life” ethical issues in the context of a 
concrete personalized medicine program, CARPEM.
Methods
Analysis of practices
To describe current practices in CARPEM and organize 
the sharing of knowledge between all stakeholders, we 
created two distinct multidisciplinary committees: an 
“Expert Committee”, gathering healthcare and research 
professionals, and a “Patient Committee”, gathering 
patients and patient representatives. The team of the 
Laboratory of Medical Ethics (LEM) of University Paris 
Descartes provided mediation between both committees. 
The LEM team is in charge of the agenda and minutes of 
all meetings and consists of specialists in medical ethics, 
research ethics, law, anthropology and linguistics. Partic-
ipants of each committee validated the minutes.
Expert Committee
The Expert Committee functioned as a “chat room” 
between practitioners and researchers participating in 
the medical and scientific aspects of the CARPEM pro-
gram. The committee met monthly from February 2013 
to September 2014 and quarterly thereafter until Decem-
ber 2015. The committee was involved in collecting and 
disseminating information about the aims of CARPEM. 
Healthcare and research professionals shared their expe-
riences, difficulties encountered and expectations. Each 
meeting was dedicated to a speciality involved in person-
alized medicine—oncology, biology, biomedical infor-
matics, cancer genetics, radiology, psychology, dietetic 
and primary care medicine—which ensures the continu-
ity of care between the hospital and home/rehabilitation 
unit. The LEM team presented reports of these meetings 
to the Patient Committee.
Patient Committee
The Patient Committee was set up as (1) a forum for 
exchange and communication with patients; (2) an advi-
sory committee that gathered patient expectations, fears 
or criticisms about personalized medicine; and (3) a body 
to provide recommendations and validate the delivera-
bles from the Expert Committee. The Patient Committee 
consisted of six patients participating in the CARPEM 
research program, two representatives from patient asso-
ciations and one representative of the public, together 
with the LEM team. Meetings occurred every 2 months 
from February 2013 to December 2015. The LEM team 
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presented the discussions from the Expert Committee, 
collected the views expressed in the Patient Committee, 
produced minutes for each meeting and reported them 
to the Expert Committee.
Transfer of knowledge to the public
CARPEM is committed to informing and educating 
patients and the public via its website and by producing 
educational videos [18]. Social media channels (YouTube, 
LinkedIn and Twitter) are also used. All videos are pro-
duced in French with French and English subtitles.
The subprogram ethics and Cancer organized an 
agenda for disseminating knowledge and guidelines 
through international workshops that are open to the 
public (in collaboration with the Société Française et 
Francophone d’Ethique Médicale and the International 
Institute of Research in Ethics and Biomedicine). Top-
ics were chosen to ensure audience interest in precision 
medicine and patient-centered care.
Results
Building a common knowledge base for co‑construction 
of CARPEM translational research practices
The Expert and Patient committees had numerous 
exchanges for establishing fair information processes and 
building proper practices (Fig. 1). With the emergence of 
personalized medicine, healthcare professionals in the 
Expert Committee recognized the need to consider all 
the implications of this medicine, particularly in terms of 
responsibilities and derivative practices. They acknowl-
edged that the development of personalized medicine 
would involve profound changes in practices. They felt 
that the Expert Committee, as a unique place to meet, 
balanced with the current “silo organisation” of their own 
practices and gave them the opportunity to share their 
thoughts on their expectations and concrete difficulties. 
The Expert Committee meetings were also a forum for 
professionals to hear about patient expectations, fears 
and claims as transmitted by the LEM team after each 
Patient Committee meeting. This organisation in two 
committees has resulted in a form of research ethics con-
sultation service helping professional teams to identify 
ways to address the ethical policy and social challenges 
born in TR [19, 20]. In our model, patients’ representa-
tives are closely embedded.
After a few meetings of the Patient Committee, patients 
criticized the term “personalized medicine”, the most 
common term used at the time the project started. They 
felt that this label was confusing because it suggested 
patient-centered medicine, but they came to realize that 
it refers to a molecular/genomic approach that aims for 
an overall set of objectives including preventive, predic-
tive and precision medicine. Moreover, patients realised 
that precision medicine implied the process of TR.
During their exchanges with the LEM members, all 
participants of the two committees could upgrade their 
knowledge about the ethical and legal norms for both 
practices of TR: research and healthcare. They progres-
sively understood why and how personalized medicine 
(or most appropriately, precision medicine) was erasing 
boundaries between the clinic, laboratory and healthcare 
industry.
Addressing complexity
When the two committees first met, CARPEM was creat-
ing its own TR platform by transforming existing clinical 
biorepositories into a unique research-oriented one inte-
grating large collections of patient samples together with 
clinical, pathologic and outcome data stored in a unique 
data warehouse [15, 21, 22]. The previous patient infor-
mation process was inappropriate because many human 
samples were collected during the care pathway without 
gathering any informed consent for research purposes or 
were accompanied by an obsolete care one. This lack of 
individual informed consent represented an insurmount-
able obstacle to the re-use of clinical samples for TR, 
both for ethical and legal reasons. However, the overall 
discussions highlighted the complexity of the information 
to deliver. One element of complexity patients identified 
was that at the global level, precision medicine is usually 
described as a continuum between research and care, 
whereas at the individual level, discontinuity might be the 
rule. Thus, patients understood that a patient who con-
sents to giving samples and data for precision medicine 
purposes has no assurance of therapeutic individual ben-
efit nor any kind of reciprocity. Moreover, the research 
results could expose the patient to incidental findings. 
Professionals are indeed worried about this eventuality. 
Furthermore, all stakeholders, professionals and patients, 
Fig. 1 Description of the ethics committees in CARPEM. The Expert 
Committee and the Patient Committee operated for 2 years before 
being merged into the Advisory Translational Ethics Board (ATEB)
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agreed that the complexity is due in part to the multiplic-
ity of actors involved, the technical complexity of data or 
sample gathering, and the uncertain temporality of data 
or sample re-use. They urged the need to update and 
standardize patient information and informed consent 
forms, even though building fair informed consent pro-
cesses seemed a challenge in the context of TR and preci-
sion medicine.
General recommendations from the Patient Committee
Patients and their representatives in CARPEM high-
lighted from the outset the need for their involvement 
in the design of “precision medicine”. They cited specific 
concerns.
First, they wanted information that would help them 
make informed decisions, in particular concerning the 
use and re-use of routine care data and samples. They 
also recommended clarifying the process of information 
and consent in terms of organisation and professional 
responsibilities.
Second, they were worried about how a number of sen-
sitive elements would be explained to patients: patients’ 
possible ineligibility to receive innovative treatments 
without feeling abandoned by medicine, the possible dis-
continuation of treatment due to the non-sustainability 
of some therapeutic targets, and finally, the coordination 
of their medical care within the community–hospital 
interface, not yet established.
Accordingly, the Patient Committee developed the fol-
lowing four recommendations [23]: (1) the patient and 
family should be properly informed of the freedom to 
accept or decline precision medicine or TR participa-
tion without judgment of any kind (a fair and balanced 
information should cover both the treatment options and 
the foreseeable consequences of the results); (2) privacy 
should be ensured; (3) data and/or samples collected in 
CARPEM should be used to precision medicine goals; 
and (4) patients and groups representing the public 
should be included in all decisions and processes.
Contribution of the Patient Committee to producing an 
information leaflet on searching for genetic alterations 
in cancer
The Patient Committee contributed to the elaboration of 
a leaflet describing the process for searching for genetic 
alterations in tumor by sequencing in view of a potential 
targeted therapy to be delivered during a consultation 
in oncogenetics. The committee considered important 
a number of points that would better inform patients, 
which allowed for establishing a framework for guidance: 
(1) the leaflet should use “you” as much as possible and 
information should be contextualized to the patient’s 
situation; (2) it should briefly describe the method of 
analysis comparing the genetic material found in tumor 
and blood samples; (3) it should specify the delay in com-
municating results; (4) it should address the risks of inci-
dental findings, and the option to be informed or not 
should be proposed and revised over time; (5) it should 
give details about samples and data such as storage place, 
length of conservation, and potential re-use for research 
purposes; and (6) a group of patients or their representa-
tives should carefully review all leaflets.
The leaflet produced closely followed this guidance. 
Particularly with regard to unintended outcomes, the 
discussions resulted in the following organization: (1) 
patients are informed individually about the possibility 
of incidental findings by clinician researchers, both ver-
bally and in the information leaflet and (2) the consent 
form allows the patient to express his or her preferences 
as to whether or not to be informed of the outcome. If 
the patient chooses to know the results of an inciden-
tal finding whose clinical relevance is established, this is 
done during an oncogenetic consultation. A diagnostic 
test is then proposed to the patient in order to validate 
the result of sequencing technologies.
Contribution of the Patient Committee to a consent form 
addressing the re‑use of data and samples
Professionals reported the difficulty in reusing a large 
number of data and samples collected during cancer care 
for research aims despite their potential use for research 
purposes [24, 25]. This difficulty is due to the absence 
of prior patient information and the lack of collecting 
appropriate consent for this. To handle this issue, exist-
ing consent forms were collected. Their analysis revealed 
their diversity, their lack of information on new technolo-
gies, and the need for legal and regulatory updates [26].
There was an urgent demand from professionals to have 
a generic and shared consent form that could be adapted 
to different situations. A framework for a consent form 
was worked out to support prospective research projects 
(interventional research) and another to support storage 
and retrospective research on samples and data (non-
interventional research).
The CARPEM Management Team implemented a new 
informed consent form for all cancer patients in hospi-
tals to encompass the collection of tumor samples and 
data for research. The Patient Committee discussed the 
informed consent form before its approval by a French 
legal ethics research committee. The form allows for 
conserving data and samples for future research in the 
field of cancer. The collection of tumor samples with use 
of the new consent form is ongoing. To better organize 
and improve the systematic collection and processing of 
patient consent, two biomedical engineers were recruited 
by the CARPEM in April 2015. They are working with the 
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local clinical teams to improve the circulation of patient 
information and the collection of consent.
Recognition of patients as peers in CARPEM
After 3  years of existence (2013–2015), the Expert and 
Patient committees were merged into a single commit-
tee, the Advisory Translational Ethics Board (ATEB). The 
ATEB functions as an advisory committee overseeing the 
ethical and cultural dimensions of all CARPEM projects. 
It deals with any ethical issues that might emerge dur-
ing the process of TR. It meets once per quarter. One of 
the first objectives of the ATEB was to work with both 
healthcare professionals and patients to build useful tools 
for a better understanding of a “fair exchange of infor-
mation in order to help patients make informed deci-
sions”. As a result of the patient engagement in CARPEM 
projects, a patient representative was included in the 
CARPEM Steering Committee.
Because of their active participation in CARPEM, 
patients and their representatives acquired the knowl-
edge and skills to animate the public debate on precision 
medicine. Their intervention as speakers and moderators 
to scholarly conferences is key to educating the public 
about precision medicine.
Transfer of knowledge to the public
CARPEM has produced 10 short videos (from 1 to 5 min) 
containing interviews with CARPEM researchers, and 
physicians. The videos explain precision medicine and 
how it can change clinical practice. Two videos are dedi-
cated to ethical issues, one involving an interview with 
a LEM coordinator and the other patients themselves. 
They are available on the CARPEM website (http://www.
carpem.fr).
Five 1-day workshops dedicated to ethics occurred 
between March 2013 and December 2015. They 
addressed “Complex computerized systems in health”, 
“New paradigms of personalized or precision medicine”, 
“Platforms for access to care and research”, “Social dis-
parity and health” and “Medical confidentiality, the right 
of oblivion and personalized medicine in cancer”. Confer-
ence proceedings were produced for each meeting and 
were published in French [27, 28].
Discussion
Translational research is a complex process that encom-
passes traditional biomedical research. The latter deals 
with experimentation on human subjects and origi-
nates from the ethics codes of the mid-to-late 1900s 
[10]. These codes aim to protect research participants 
(patients and volunteers) enrolled in interventional 
and physically risky research. The CARPEM program 
is dedicated to precision medicine and TR in oncology, 
benefiting patients from recent discoveries and re-for-
mulating research questions from the needs identified 
by the clinic. It integrates ethical expertise in its govern-
ance and develops ongoing empirical-ethical research to 
identify, support and fuel the debate about ethical issues 
encountered in real-life practice. To this end, patients 
were included during the entire process, giving them 
the “floor” to express their vision and expectations and 
engage them in constructing an appropriate normative/
ethical framework.
This organization in two committees has resulted in a 
form of research ethics consultation service helping pro-
fessional teams to identify ways to address the ethical 
policy and social challenges born in TR [19, 20]. In our 
model, patients’ representatives are closely embedded.
A first aim of the ethics program was to facilitate 
knowledge transfer among patients, their representatives, 
and the different kinds of healthcare professionals so as 
to build a common language and common understand-
ing. This aim was realized by the interaction of two ethics 
committees, the Expert Committee and Patient Commit-
tee, that met for more than 2 years before being merged. 
This is key to enabling effective patient involvement not 
only as active participants but also as real partners whose 
inputs are valuable throughout the process [29]. Such a 
transfer of knowledge was essential to ensure transpar-
ency and to allow patients and society to accept these 
new practices [13].
A second—and still ongoing—objective was the iden-
tification of the ethical issues at stake. One of the main 
issues arising from the committee discussions and high-
lighted by patients was the primary dual intentionality of 
TR, bridging care and research pathways. Recently, Hos-
tiuc et al. [7] divided TR into a succession of six operating 
phases, starting with fundamental research and ending 
with the implementation of social policies, as a result of 
the whole translation process. Indeed, “translation” usu-
ally refers to how biomedical science should produce 
a return of investment by bridging the gap between the 
amount of knowledge produced and the expected benefit, 
the “bench-to-bedside” approach [30, 31]. In CARPEM, 
particular attention in the translation movement was 
paid to the bedside-to bench approach because TR rests 
on translational researchers who are also physicians at 
the interface between the clinic and research. Indeed, a 
very important part of the translational process consists 
of harvesting and storing patient samples and data col-
lected for both diagnosis or care and research. This pro-
cess is insufficient as such and has to be accompanied 
by the questions posed by clinician researchers. This is 
indeed an effective mean to transfer the clinical problems 
that need to be addressed into the laboratory research 
environment.
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Patients became aware of the dual translation move-
ment and accepted this. They provided a number of 
recommendations related to the information and con-
sent process for the use of data or samples for research, 
thereby reaffirming their attachment to the principle 
of autonomy. Finally, they participated in elaborating 
two kinds of information leaflets, one for searching for 
genetic alterations in tumors with potential medical con-
sequence for the patient and one concerning the future 
use of data or samples. This process agrees with recog-
nizing that the legal and ethical frameworks in precision 
medicine and that TR must be built with a patient-cen-
tered approach, taking into account the individual con-
cerns and expectations of patients [7, 13, 14, 32, 33].
This process has been a first step in harmonizing the 
ethical procedures in CARPEM by pragmatic consensual 
solutions consistent with the existing legal and ethical 
framework and convenient to all parties. Thus, the ethical 
process was shaped in the research program by integrat-
ing these approved measures as structural constraints 
while respecting the scientific objectives. Indeed, a rec-
ommendation was that the modernization of the cur-
rent regulatory landscape for precision medicine should 
involve mobilizing as much as possible the existing regu-
latory instruments and ethical principles [13].
However, our results revealed ethical issues that need 
to be worked out at the international level when no 
pragmatic and consensual solutions compatible within 
the current framework can be found. Consent mod-
els for TR represents one of the core ethical, legal, and 
social issues in bioethics. For example, a concern is that 
the broad consent process adopted by many studies as 
a practical solution for unforeseen secondary research 
aims may actually reduce the trust between participants 
and researchers [9, 24]. Indeed, the Patient Committee 
argued for a specific and “related conditions” consent 
[9] for re-use of data and samples limited to the goal of 
precision medicine. The committee recommended, for 
any other purpose, a labelled ethical research commit-
tee statute on the need to re-contact patients, taking into 
account the terms of the initial consent form.
Our results are consistent with the opinion of some 
authors who stressed the need for a specific set of 
bioethical guidelines for TR and proposed the concept of 
“translational ethics” [7, 10–12]. The authors emphasize 
that this set should be developed according to the steps 
or phases identified in the process and to the entire trans-
lational research process. As early as 2000, Kagarise and 
Sheldon introduced “translational ethics’ in an attempt 
to account for the intertwining of research and clinical 
practices in TR [10]. The authors recommended a model 
of procedural ethics based on autonomy and informed 
consent. They stressed the difficulty in providing such 
informed consent in unprecedented situations inher-
ent in modern practices and advocated for an initial and 
ongoing educational dialogue between patients and phy-
sicians that would require new competencies for physi-
cians [10]. Their reasoning was developed from a moral 
and professional responsibility perspective.
Our approach goes further: first, it embeds the patient 
perspective from the beginning in a concrete academic 
and institutional TR program, and second, it addresses 
the acceptability of the translational research process 
itself. In 2009, Cribb [12], discussing the concept of 
translational ethics under the perspective of the theory–
practice gap in medical ethics, highlighted the interest 
of reflecting on the bridge linking ethical scholarship to 
practice. He argued that translational ethics should refer 
to the “what” and “how” dimensions. The “what” implies 
reflection on the meaning of practices, step by step and 
globally, whereas the “how” considers their modalities 
of implementation. For Cribb, medical ethics transla-
tion cannot work on the “how” dimension in isolation 
but needs to account for whether the resulting actions 
are ethically justifiable. By doing this, Cribb stresses the 
risk of “ethics dumping” and blind transposition of ethi-
cal regulations that are not adapted to current practices. 
To avoid this risk and to facilitate the acceptance of new 
practices by the public at both the individual and global 
levels, the patient-centered approach is key [33]. We 
applied this approach in CARPEM and demonstrated its 
relevance.
Conclusions
The current debate surrounding precision medicine and 
translational research focuses merely on the need for a 
new international regulation framework, but a number 
of unexplored ethical issues need to be addressed in the 
“real life” context. A way to progress is to open the dialog 
between professionals, patients and society. One hypoth-
esis in CARPEM was that empirical ethical research 
based on a patient-centered approach should help estab-
lish a fair model for coordination and support actions 
for translational cancer research. This involves striking 
a balance between the regulatory framework, researcher 
needs and patient expectations. Our results demonstrate 
the relevance of including patients and representatives 
to achieve this primary goal and to ensure transparency 
and trust. The recognition of patients as peers by profes-
sionals led to their concrete participation in framing pre-
cision medicine practices and to their participation, as 
ambassadors, in diffusing knowledge to the public. In the 
end, they were integrated as co-deciders in the steering 
committee.
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